Hepatitis C virus as a systemic disease: reaching beyond the liver

Hepatology International

Volumn 10, Issue 3, 2016, Pages 415-423

  Gill, Kirat ^a   Ghazinian, Hasmik ^b   Manch, Richard ^a   Gish, Robert ^c,d  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b 'Nork Marash' Medical Center   (Armenia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d National Viral Hepatitis Roundtable   (United States)

Author keywords

Chronic hepatitis C; Diabetes mellitus; Extrahepatic manifestations; HCV brain syndrome; Insulin resistance; Lymphoproliferative disorder; Mixed cryoglobulinemia; Renal failure

Indexed keywords

CRYOGLOBULIN; PEGINTERFERON; RIBAVIRIN;

ACUTE KIDNEY FAILURE; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC HEPATITIS C; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; COMORBIDITY; CORONARY ARTERY DISEASE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRY EYE; GLOMERULONEPHRITIS; HEPATITIS C VIRUS; HUMAN; IMMUNE COMPLEX DISEASE; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LUNG FIBROSIS; LYMPHOPROLIFERATIVE DISEASE; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PURPURA; RAYNAUD PHENOMENON; RETINOPATHY; REVIEW; RISK FACTOR; SIALOADENITIS; SJOEGREN SYNDROME; SYSTEMIC DISEASE; THYROID DISEASE; CEREBROVASCULAR DISORDERS; COMPLICATION; DIABETES MELLITUS, TYPE 2; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS;

CEREBROVASCULAR DISORDERS; CRYOGLOBULINEMIA; DIABETES MELLITUS, TYPE 2; GLOMERULONEPHRITIS; HEPACIVIRUS; HEPATITIS C; HUMANS; INSULIN RESISTANCE; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84949569352     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9684-3     Document Type: Review

References (87)

1. Cheng Z, Zhou B, Shi X, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J (Engl). 2014;127:1206–1210.
2. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. multidepartment virus C. Arthritis Rheum. 1999;42:2204–2212.
3. Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006;8:53–59.
4. Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–173.
5. Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012;379:348–360.
6. Lauletta G, Russi S, Conteduca V, et al. Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol. 2012;2012:502156.
7. Lunel FM, Musset L. Hepatitis C virus infection and cryoglobulinemia. Viral Hepat Rev. 1996;2:111–124.
8. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani ES, Duval J, Dhumeaux, D. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994;19(4):841–8. doi:10.1002/hep.1840190407.
9. Jadali Z, Alavian SM. Autoimmune diseases co-existing with hepatitis C virus infection. Iran J Allergy Asthma Immunol. 2010;9:191–206.
10. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenstrom’s macroglobulinemia. Crit Rev Oncol Hematol. 2008;67:172–185.
11. Zaidan M, Mariotte E, Galicier L, et al. Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis. Ann Intensive Care. 2012;2:31.
12. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014;20:7544–7554.
13. Perico N, Cattaneo D, Bikbov B, et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207–220.
14. Schamberg NJ, Lake-Bakaar GV. Hepatitis C virus-related mixed cryoglobulinemia: pathogenesis, clinical manifestations, and new therapies. Gastroenterol Hepatol (N Y). 2007;3:695–703.
15. Longo DFA, Kasper DL, Hauser S, Jameson J, Loscalzo J. Harrison’s Principles of Internal Medicine. 18th ed. New York: McGraw-Hill; 2011.
16. Gandolfo S, Carrozzo M. Lichen planus and hepatitis C virus infection. Minerva Gastroenterol Dietol. 2002;48:89.
17. Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis. 2010;16:601–612.
18. Fortune BE, Francis S, Forman LM. Hepatitis C virus therapy-related skin manifestations. Gastroenterol Hepatol (N Y). 2010;6:326–328.
19. Akriviadis EA, Xanthakis I, Navrozidou C, et al. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol. 1997;25:612–618.
20. Dedania B, Wu GY. Dermatologic extrahepatic manifestations of hepatitis C. J Clin Transl Hepatol. 2015;3:127–133.
21. Kapoor R, Johnson RA. Necrolytic acral erythema. N Engl J Med. 2011;364:1479–1480.
22. Tabibian JH, Gerstenblith MR, Tedford RJ, et al. Necrolytic acral erythema as a cutaneous marker of hepatitis C: report of two cases and review. Dig Dis Sci. 2010;55:2735–2743.
23. Ko HM, Hernandez-Prera JC, Zhu H, et al. Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol. 2012;2012:740138.
24. Tsoumani A, Theopistos V, Katsanos K, et al. Treatment and non-treatment related ocular manifestations in patients with chronic hepatitis B or C. Eur Rev Med Pharmacol Sci. 2013;17:1123–1131.
25. Stepanova M, Lam B, Younossi Y, et al. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat. 2012;19:341–345.
26. Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. Hepatol Int. 2013;7(Suppl 2):782–789.
27. Younossi ZM, Stepanova M, Nader F, et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37:647–652.
28. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38:50–56.
29. Wang CS, Wang ST, Yao WJ, et al. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166:196–203.
30. Chien CH, Lin CL, Hu CC, et al. Clearance of hepatitis c virus improves insulin resistance during and after peginterferon and ribavirin therapy. J Interferon Cytokine Res 2015. doi:10.1089/jir.2014.0200.
31. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15:1537–1547.
32. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831–844.
33. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet. 1992;339:321–323.
34. Carrozzo M, Scally K. Oral manifestations of hepatitis C virus infection. World J Gastroenterol. 2014;20:7534–7543.
35. Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology. 2009;392:1–10.
36. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–3044.
37. Krystyna A, Safi T, Briggs WM, et al. Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration. Int Braz J Urol. 2011;37:223–229.
38. Nagao Y, Sata M, Tanikawa K, et al. High prevalence of hepatitis C virus antibody and RNA in patients with oral cancer. J Oral Pathol Med. 1995;24:354–360.
39. Fallahi P, Ferrari SM, Giuggioli D, et al. Thyroid involvement in hepatitis C-associated mixed cryoglobulinemia. Hormones (Athens). 2014;13:16–23.
40. Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behavior and treatment. World J Gastroenterol. 2014;20:11054–11061.
41. Su FH, Chang SN, Chen PC, et al. Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study. BMC Cancer. 2011;11:495.
42. Larrey D, Bozonnat MC, Kain I, et al. Is chronic hepatitis C virus infection a risk factor for breast cancer? World J Gastroenterol. 2010;16:3687–3691.
43. Arase Y, Suzuki F, Suzuki Y, et al. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol. 2008;14:5880–5886.
44. Meliconi R, Andreone P, Fasano L, et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax. 1996;51:315–317.
45. Rifai MA, Indest D, Loftis J, et al. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol. 2006;9:508–519.
46. Butt AA, Khan UA, McGinnis KA, et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007;14:890–896.
47. Matthews AM, Huckans MS, Blackwell AD, et al. Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord. 2008;10:266–270.
48. Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006;66:155–174.
49. Rowan PJ, Al-Jurdi R, Tavakoli-Tabasi S, et al. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol. 2005;39:731–736.
50. Dalgard O, Egeland A, Skaug K, et al. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology. 2004;39:74–80.
51. Boscarino JA, Lu M, Moorman AC, et al. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS). Hepatology. 2015;61:802–811.
52. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104:2439–2448.
53. Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon. 2013;13:e8340.
54. Mao XR, Zhang LT, Chen H, et al. Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients. Exp Ther Med. 2014;8:133–140.
55. Broussolle C, Steineur MP, Bailly F, et al. [Hepatitis C virus infection and thyroid diseases]. Rev Med Interne. 1999;20:766–773.
56. Hadziyannis SJ. Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci. 1996;41:63S–74S.
57. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158:1445–1448.
58. World Health Organization. The top 10 causes of death. 2014. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 20 Sept 2014.
59. Wong RJ, Kanwal F, Younossi ZM, et al. Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig Dis Sci. 2014;59:1586–1593.
60. Liao CC, Su TC, Sung FC, et al. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS ONE. 2012;7:e31527.
61. He H, Kang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS ONE. 2013;8:e81305.
62. Adinolfi LE, Zampino R, Restivo L, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410–3417.
63. Lee MH, Yang HI, Wang CH, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke. 2010;41:2894–2900.
64. Boddi M, Abbate R, Chellini B, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010;47:72–75.
65. Adinolfi LE, Restivo L, Guerrera B, et al. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis. 2013;231:22–26.
66. Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49:225–232.
67. Roed T, Lebech AM, Kjaer A, et al. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging. 2012;32:421–430.
68. Alyan O, Kacmaz F, Ozdemir O, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J. 2008;72:1960–1965.
69. Hsu YH, Muo CH, Liu CY, et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9 years population-based cohort study. J Hepatol. 2015;62:519–525.
70. Demir C, Demir M. Effect of hepatitis C virus infection on the right ventricular functions, pulmonary arterypressure and pulmonary vascular resistance. Int J Clin Exp Med. 2014;7:2314–2318.
71. Mariotto S, Ferrari S, Monaco S. HCV-related central and peripheral nervous system demyelinating disorders. Inflamm Allergy Drug Targets. 2014;13:299–304.
72. Abdelkader NA, Zaky DZ, Afifi H, et al. Neuropathies in hepatitis C-related liver cirrhosis. Indian J Gastroenterol. 2014;33:554–559.
73. Biasiotta A, Casato M, La Cesa S, et al. Clinical, neurophysiological, and skin biopsy findings in peripheral neuropathy associated with hepatitis C virus-related cryoglobulinemia. J Neurol. 2014;261:725–731.
74. Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002;76:10064–10068.
75. Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002;76:600–608.
76. Forton DM, Karayiannis P, Mahmud N, et al. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 2004;78:5170–5183.
77. Fletcher NF, Wilson GK, Murray J, et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology. 2012;142:634–643.
78. Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol. 2009;83:1312–1319.
79. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–439.
80. Chiu WC, Tsan YT, Tsai SL, et al. Hepatitis C viral infection and the risk of dementia. Eur J Neurol. 2014;21:1068.
81. Abdel Rahman TT, Abou Hashem RM, Abdel Guaad MA, et al. Executive functions in chronic hepatitis C virus-infected elderly patients. Geriatr Gerontol Int 2014 [Epub ahead of print].
82. Umaki TM, Denney RL. Neurocognitive deficits associated with the hepatitis C virus among incarcerated men. Clin Neuropsychol. 2013;27:426–436.
83. Huckans M, Seelye A, Parcel T, et al. The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder. J Int Neuropsychol Soc. 2009;15:69–82.
84. Isaacs D, Abdelaziz N, Keller M, et al. Measuring the response of extrahepatic symptoms and quality of life to antiviral treatment in patients with hepatitis C. Hepat Res Treat. 2013;2013:910519.
85. Kayali Z, Labrecque DR, Schmidt WN. Treatment of hepatitis C cryoglobulinemia: mission and challenges. Curr Treat Options Gastroenterol. 2006;9:497–507.
86. Gerber L, Estep M, Stepanova M, et al. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis c virus infection. Clin Gastroenterol Hepatol. 2015. doi:10.1016/j.cgh.2015.07.035.
87. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337–345.